Sort by
Previous Page Page 2 of 8 Next Page
  1. Review

    Novel melanoma therapy

    With the rapid succession of new effective agents for melanoma in the recent years, the paradigm for treatment of metastatic melanoma is changing. The success of combining multiple effective agents compared wi...

    Eddy C. Hsueh and Kalyan C. Gorantla

    Experimental Hematology & Oncology 2016 5:23

    Published on: 8 August 2016

  2. Research

    Effects of molecularly targeted therapies on murine thymus: highly selective mTOR inhibitors induce reversible thymic involution

    Blocking mTOR (molecular target of rapamycin) by sirolimus has been shown to suppress cellular respiration. The bearing of this impaired cellular bioenergetics on the mode-of-action of mTOR inhibitors has yet ...

    Suleiman Al-Hammadi, Saeeda Almarzooqi, Alia Albawardi and Abdul-Kader Souid

    Experimental Hematology & Oncology 2016 5:22

    Published on: 29 July 2016

  3. Case report

    Acute lymphoblastic leukemia with e1a3 BCR/ABL fusion protein. A report of two cases

    B Acute Lymphoblastic leukemia (B-ALL) with Philadelphia chromosome (Ph′) is a neoplasm of lymphoblast committed to the B cell lineage. The clinical presentation of B-ALL Ph′+ is similar to B-ALL, but is more ...

    Bernardo López-Andrade, Francesca Sartori, Antonio Gutiérrez, Lucia García, Vanesa Cunill, María Antonia Durán, Antonia Sampol, Marta Bernués, Julio Iglesias, Rafael Ramos, Josep Lladó, María Sánchez, Juan Carlos Amat and Jordi Martínez-Serra

    Experimental Hematology & Oncology 2016 5:21

    Published on: 29 July 2016

  4. Case report

    Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG

    The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy.

    Katherine Linder, Deepthi Gandhiraj, Madhura Hanmantgad, Karen Seiter and Delong Liu

    Experimental Hematology & Oncology 2016 5:20

    Published on: 26 July 2016

  5. Letter to the Editor

    p27KIP1 and PTEN cooperate in myeloproliferative neoplasm tumor suppression in mice

    PTEN acts as a phosphatase for PIP3 and negatively regulates the PI3K/AKT pathway, and p27KIP1 is a cyclin-dependent kinase inhibitor that regulates the G1 to S-phase transition by binding to and regulating the a...

    Jingchen Shao, Susann Li, Lars Palmqvist, Linda Fogelstrand, Stella Y. Wei, Kiran Busayavalasa, Kui Liu and Viktor M. Liu

    Experimental Hematology & Oncology 2016 5:17

    Published on: 30 June 2016

  6. Case report

    Systemic inflammatory response syndrome in a patient diagnosed with high grade inflammatory triple negative breast cancer: a case report of a potentially rare paraneoplastic syndrome

    Inflammatory breast cancer is a complex pathological entity associated with poor outcomes. This loco-regional disease is characterised by a rapid clinical course in the presence breast erythema and infiltratio...

    Piers R. Boshier, Rosie Sayers, Dimitri J. Hadjiminas, Charles Mackworth-Young, Susan Cleator and Daniel R. Leff

    Experimental Hematology & Oncology 2016 5:16

    Published on: 22 June 2016

  7. Review

    Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy

    Hormonal manipulation plays a significant role in the treatment of advanced hormone naïve prostate cancer and castration-resistant prostate cancer (CRPC) with or without previous chemotherapy. Combination of g...

    Thy Pham, Martin C. Sadowski, Huika Li, Derek J. Richard, Michael C. d’Emden and Kerry Richard

    Experimental Hematology & Oncology 2016 5:15

    Published on: 22 June 2016

  8. Research

    Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control study

    Myeloproliferative neoplasms (MPNs) including the classic entities; polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis are rare diseases with unknown aetiology. The MOSAICC study,...

    Mary Frances McMullin, Glen James, Andrew S. Duncombe, Frank de Vocht, Lin Fritschi, Mike Clarke and Lesley A. Anderson

    Experimental Hematology & Oncology 2016 5:14

    Published on: 26 May 2016

  9. Research

    A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes

    Dys-megakaryopoiesis is defined as ≥10 % of dysplastic megakaryocytes in bone marrow smears by the World Health Organization. However, concordance rates for dysplastic megakaryocytes between different observer...

    Gege Feng, Robert Peter Gale, Wen Cui, Wenyu Cai, Gang Huang, Zefeng Xu, Tiejun Qin, Yue Zhang, Bing Li, Liwei Fang, Hongli Zhang, Lijuan Pan, Naibo Hu, Shiqiang Qu, Jingya Wang, Yajuan Cui…

    Experimental Hematology & Oncology 2016 5:12

    Published on: 27 April 2016

  10. Research

    A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

    The immunomodulatory agent pomalidomide in combination with low-dose dexamethasone has demonstrated efficacy and safety for the treatment of relapsed and refractory multiple myeloma (RRMM) in phase 2 and 3 tri...

    Tatsuo Ichinohe, Yoshiaki Kuroda, Shinichiro Okamoto, Kosei Matsue, Shinsuke Iida, Kazutaka Sunami, Takuya Komeno, Kenshi Suzuki, Kiyoshi Ando, Masafumi Taniwaki, Kensei Tobinai, Takaaki Chou, Hitomi Kaneko, Hiromi Iwasaki, Chie Uemura, Hiromi Tamakoshi…

    Experimental Hematology & Oncology 2016 5:11

    Published on: 18 April 2016

  11. Erratum

    Erratum to: New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies

    Clémentine Gamonet, Elodie Bole-Richard, Aurélia Delherme, François Aubin, Eric Toussirot, Francine Garnache-Ottou, Yann Godet, Loïc Ysebaert, Olivier Tournilhac, Caroline Dartigeas, Fabrice Larosa, Eric Deconinck, Philippe Saas, Christophe Borg, Marina Deschamps and Christophe Ferrand

    Experimental Hematology & Oncology 2016 5:10

    Published on: 14 April 2016

    The original article was published in Experimental Hematology & Oncology 2016 5:7

  12. Case report

    Rare MLL-ELL fusion transcripts in childhood acute myeloid leukemia—association with young age and myeloid sarcomas?

    The chromosomal translocation t(11;19)(q23;p13) with a breakpoint within subband 19p13.1 is found mainly in acute myeloid leukemia (AML) and results in the MLL-ELL fusion gene. Variations in the structure of MLL-

    Ioannis Panagopoulos, Ludmila Gorunova, Gitte Kerndrup, Signe Spetalen, Anne Tierens, Liv T. N. Osnes, Kristin Andersen, Lil-Sofie Ording Müller, Marit Hellebostad, Bernward Zeller and Sverre Heim

    Experimental Hematology & Oncology 2016 5:8

    Published on: 5 March 2016

  13. Research

    New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies

    CD20 is a B cell lineage–specific marker expressed by normal and leukemic B cells and targeted by several antibody immunotherapies. We have previously shown that the protein from a CD20 mRNA splice variant (D3...

    Clémentine Gamonet, Elodie Bole-Richard, Aurélia Delherme, François Aubin, Eric Toussirot, Francine Garnache-Ottou, Yann Godet, Loïc Ysebaert, Olivier Tournilhac, Caroline Dartigeas, Fabrice Larosa, Eric Deconinck, Philippe Saas, Christophe Borg, Marina Deschamps and Christophe Ferrand

    Experimental Hematology & Oncology 2016 5:7

    Published on: 1 March 2016

    The Erratum to this article has been published in Experimental Hematology & Oncology 2016 5:10

  14. Research

    Nucleotide excision repair deficiency in melanoma in response to UVA

    The causative link between UV exposure and melanoma development is well known, however the mechanistic relationship remains incompletely characterised. UVA and UVB components of sunlight are implicated in mela...

    Heather C. Murray, Vicki E. Maltby, Doug W. Smith and Nikola A. Bowden

    Experimental Hematology & Oncology 2016 5:6

    Published on: 24 February 2016

  15. Rapid communication

    Deregulated expression of the HSP40 family members Auxilin-1 and -2 is indicative of proteostasis imbalance and predicts patient outcome in Ph+ leukemia

    Proteostasis is defined by the orchestrated control of anabolic and catabolic protein pathways. Disruption of proteostasis results in cell stress and adaptation to proteostasis imbalance is mediated by adaptiv...

    Margherita Vieri, Huimin Geng, John B. Patterson, Jens Panse, Stefan Wilop, Afshin Samali, Eric Chevet and Behzad Kharabi Masouleh

    Experimental Hematology & Oncology 2016 5:5

    Published on: 9 February 2016

  16. Research

    Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review

    Hydroxyurea (HU) is among the most commonly used cytoreductive treatments for polycythemia vera (PV), but previous research and clinical experience suggest that not all patients respond optimally, consistently...

    Shreekant Parasuraman, Marco DiBonaventura, Kelly Reith, Ahmad Naim, Kristen Concialdi and Nicholas J. Sarlis

    Experimental Hematology & Oncology 2016 5:3

    Published on: 1 February 2016

  17. Research

    Identification of AIM2 as a downstream target of JAK2V617F

    The gain-of-function mutation JAK2V617F is frequently found in Philadelphia-chromosome-negative myeloproliferative neoplasm (MPN) patients. However, the tumorigenic properties of JAK2V617F have mostly been cha...

    Ei Leen Liew, Marito Araki, Yumi Hironaka, Seiichi Mori, Tuan Zea Tan, Soji Morishita, Yoko Edahiro, Akimichi Ohsaka and Norio Komatsu

    Experimental Hematology & Oncology 2016 5:2

    Published on: 28 January 2016

  18. Case report

    Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent

    Although the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) has been improved by the addition of rituximab to standard chemotherapy, almost one-third fails or relapses after first line...

    Patrizia Mondello, Vincenzo Pitini, Valeria Barresi, Elliott Joseph Brea, Cristian Di Mirto, Carmela Arrigo, Salvatore Cuzzocrea and Michael Mian

    Experimental Hematology & Oncology 2016 5:1

    Published on: 6 January 2016

  19. Case report

    Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma

    The programmed death 1 (PD-1) receptor is expressed by activated T-cells and engaged by ligands PD-L1 and PD-L2 normally expressed by infiltrating immune cells in response to viral infection. The PD-1/PD-L1 ax...

    Diwakar Davar, Mark A. Socinski, Sanja Dacic and Timothy F. Burns

    Experimental Hematology & Oncology 2015 4:34

    Published on: 14 December 2015

Previous Page Page 2 of 8 Next Page